Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ICAAC In Brief: Gilead's adefovir dipivoxil

Executive Summary

Gilead's adefovir dipivoxil: Phase I/II trial results in 15 patients show adefovir 125 mg once daily for 28 days decreases hepatitis B viral load by 97% or 1.8 log compared to a 7% increase in viral load in patients receiving placebo. Patients' viral levels returned to baseline one to six weeks after discontinuing adefovir therapy. Side effects with adefovir included nausea and transient hepatic transaminase elevations. Adefovir (GS 840) is in Phase II/III studies for combination treatment of HIV infection...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS028883

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel